These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28527857)

  • 1. Novel Immunologic Approaches to Melanoma Treatment.
    Escandell I; Martín JM; Jordá E
    Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 6. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 9. PD-1 and PD-L1 antibodies for melanoma.
    Tsai KK; Zarzoso I; Daud AI
    Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Biomarkers for Melanoma Immunotherapy.
    Twitty CG; Huppert LA; Daud AI
    Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
    Li TJ; Wang WQ; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma: smart therapeutic strategies in immuno-oncology.
    Eggermont AM; Robert C
    Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.